NurExone Biologic Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NurExone Biologic Inc. engages in the development of exosome-based regenerative therapies for central nervous system injuries, operating primarily through its ExoTherapy platform to create exosome-loaded nanodrugs, with ExoPTEN as its lead product candidate for acute spinal cord injury and related CNS conditions; the company also pursues membrane-bound extracellular vesicle technology for non-invasive, off-the-shelf treatments and partnerships to license its platform to the biopharma industry. Headquartered in Toronto, Canada, NurExone Biologic was founded in 2020 and is listed on the TSX Venture Exchange (NRX) and in OTC markets (NRXBF), with additional listings that support its global outreach. The business focuses on developing minimally invasive, targeted therapies delivered via extracellular vesicles to address spinal cord injuries, traumatic brain injuries, glaucoma, and other neurological injuries, while pursuing collaborations, licensing agreements, and potential strategic acquisitions to expand indications and geographic reach. The company emphasizes a dual strategy: advancing internal ExoTherapy candidates toward clinical programs and monetizing its platform through partnerships and technology licensing to biopharmaceutical developers seeking novel exosome-based delivery solutions. NurExone operates with a global horizon, aiming to establish regulatory progress in major markets including the United States and Europe, while exploring opportunities in Canada and other regions where CNS injury therapies are in demand. The corporate structure includes a focus on research and development, platform licensing, and strategic alliances to accelerate commercialization, subject to ongoing corporate developments and capital market activities.
NurExone Announces Closing of Non-Brokered Private Placement
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
Water Tower Research Publishes Initiation of Coverage Report on NurExone Biologic, Inc., “A Novel Exosome Therapy Platform at the Frontier of CNS Regeneration”
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
NurExone Announces Corporate Updates
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises